Silent auctions for medical research foundations, set up in minutes

Do not promise a cure

"Help us find a cure" is the sector's standard appeal and it is a claim about the future that nobody is in a position to make. Most research does not succeed; that is what research is.

The cost of the standard language is not only ethical. Donors who believe they funded a cure and see none conclude that the money went nowhere, and that belief is the churn problem underneath the whole category.

• Describe what the money buys — a year of a fellowship, a piece of equipment, a pilot study — not what it will achieve
• Report on work done rather than problems solved: papers, trials opened, techniques developed, questions answered
• Say plainly that most projects do not produce a treatment, and that funding the ones that might is how the ones that do get found
• Never imply that a specific donation caused a specific advance
• And never suggest a timeline for a breakthrough

Donors handle this better than the sector assumes. People who fund research generally understand that research fails, and an organization that says so sounds like scientists rather than marketers — which is what its donors chose it for.

Sell the mechanism, which is real

The reframing that makes everything else work. A foundation cannot sell an outcome, but it can sell an input — and research inputs are concrete, purchasable and surprisingly interesting.

• A year of a postdoctoral fellowship, which is a real salary for a real person
• A pilot grant, which funds the preliminary data that unlocks larger funding
• A specific instrument, with its price
• A year of a tissue bank, a registry or a cohort's follow-up
• Sequencing runs, assays, animal model development, statistical support
• A summer studentship, which is how researchers enter the field

The pilot grant is the item to explain, because its leverage is genuinely striking and almost nobody outside science knows about it: named research sponsorship.

Patient stories are the sharpest constraint you have

They are also the strongest material, which is exactly why the discipline matters.

A person who tells their diagnosis publicly cannot untell it. It reaches employers, insurers, colleagues, and family members who may not have known — and for a genetic condition it discloses information about relatives who never consented at all.

• Only where the person has decided, with a real understanding of the permanence and reach
• Written consent for this specific use, not a general one signed years ago
• A genuine ability to withdraw, including after publication
• Nothing about a genetic condition without considering the relatives it implicates
• Never solicited by clinical staff, whose relationship makes the ask unfree
• And never a child's diagnosis published by a parent without weighing what that child will inherit as an adult

The last point is the one to raise gently and firmly. A parent has the right to tell their own story; a child's medical history published now will be searchable when they are applying for jobs.

The overhead question, and the honest answer

Research donors ask what proportion reaches the bench, and the honest answer includes things they may not expect: peer review costs money, grant administration costs money, and the indirect costs an institution charges are real rather than waste.

A foundation that explains what a grant actually pays for — and why a vanishingly low overhead ratio would mean nobody was checking the science — is having a better conversation than one defending a percentage.

Working it out from an affected community

Smaller than a general health charity's audience and far more committed, with a long horizon.

• Affected families, patients and bereaved families, each reaching an extended network
• Clinicians and the professional network around the field
• The research institution's own community

The full method: how much can a foundation raise?

When an auction is the wrong instrument

For endowed chairs and major research infrastructure, which are major gift conversations. If the compelling material would require a patient to disclose more than they should, build the campaign on the science instead. And where a hospital already fundraises from the same community for buildings and equipment, coordinate: hospitals.

Affected families are your base and need protecting

In a disease-specific foundation, the people who give most are patients, survivors and bereaved families — and they are giving from inside the experience the organization exists because of.

• Bereaved families frequently want to fundraise, and that is theirs to choose — not something to be recruited into
• Anniversary and memorial campaigns carry real weight and should be led by the family
• Be careful asking somebody in active treatment to do anything
• Do not let a family's involvement become an obligation they cannot withdraw from
• And be ready for the campaign to reach people newly diagnosed, for whom the material lands very differently

That last point shapes the copy. Somebody diagnosed last week may read your campaign, and language written to alarm donors reads to them as a prognosis.

Industry money has conditions

Pharmaceutical, device and biotech companies fund research foundations, and that relationship carries constraints an events committee will not know about.

• Transparency and reporting requirements apply to industry payments in many jurisdictions
• The institution's own conflict of interest policies apply to researchers as well as to the foundation
• A sponsor must not influence what is funded, what is published, or how results are described
• Product promotion at a patient-facing event raises its own questions
• And accepting industry money at all is a policy decision some foundations take deliberately either way

Settle the policy before an offer arrives, not while somebody is holding a cheque.

Nothing that resembles medical advice or access

• No item offering diagnosis, treatment, a second opinion or a consultation
• Nothing implying priority in a trial, a waiting list or a clinic
• No claim about a treatment's efficacy or availability
• No unproven or unapproved intervention, in any framing
• And a lab tour is not a clinical visit — keep the two visibly separate

The trial access line matters most. Trial eligibility is determined by protocol and nothing else, and any suggestion that a donation could affect it is both untrue and corrosive to the trust the whole enterprise runs on.

General information, not legal or medical advice. Claims about research outcomes, treatments and trials are regulated in ways general fundraising copy is not, and patient privacy carries obligations beyond ordinary consent — your own counsel and your research leadership should read anything public before it is published.

Twelve weeks, around grant deadlines

• Week 12 — laboratory access lots agreed directly with investigators and cleared with the institution; industry policy confirmed at board level
• Week 12 — every consent for a patient story checked as current and specific to this use
• Week 10 — affected families, for networks and contacts rather than only items
• Week 8 — clinicians and the institution's wider community
• Week 6 — scientific suppliers and industry, with the policy settled
• Week 4 — general business and gap-filling
• Week 2 — catalogue closed; every claim read by somebody scientific

Work around grant submission deadlines and academic terms, which govern researcher availability far more than the fundraising calendar does.

Three jobs, and one is a scientist

• Claims review — somebody scientific reads every public word. No cure, no timeline, no implication that one donation caused one advance
• Consent — specific, current, written, withdrawable, and never solicited by clinical staff whose relationship makes the ask unfree
• Access lots — investigators asked directly, caps agreed, and the good communicators identified

Where these auctions go wrong

• "Help us find a cure," which is a claim about the future nobody can make and which produces donors who later conclude the money went nowhere
• A patient story published under an old general consent
• A child's diagnosis published by a parent without weighing what that child inherits as an adult
• Anything implying trial priority, which is untrue and corrosive
• A clinician on the board offering a consultation, which is medical care rather than a lot
• A donated genetic testing kit, which sounds apt and carries counselling implications an auction cannot support
• Industry money accepted without a policy, decided while somebody holds a cheque
• Alarm-framed copy read by somebody diagnosed last week, to whom it reads as a prognosis

What it costs, and the honesty that pays

Access lots cost staff hours. The rest is ordinary.

Worth putting to a board: reporting a funded project that did not work is the single strongest thing a research foundation can do for donor trust, because it demonstrates that the reporting is real. The sector's instinct is to report only successes, which is exactly why donors suspect the successes.

After it closes

• Tell every sponsor who was funded, what they worked on and what happened — including where it did not work
• Report on process rather than outcome: papers, trials opened, techniques developed
• Publish what past pilot grants went on to attract, where you have the figures
• Thank the investigators who gave access, and record who is a good communicator
• Keep the consent records, dated, with their scope